Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in DXB?
Dimerix: THE INVESTMENT CASE

Dimerix: Access latest PPT from Proactive's CEO Sessions

Kathy Harrison talked pending milestone news with investors.
Dimerix: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: DXB The Big Picture
Kathy Harrison, CEO, Dimerix

Dimerix’ (ASX:DXB) chief executive officer, Kathy Harrison, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April and Sydney on Wednesday, 12th April.

The company will have milestone news flow in coming months from its Phase II clinical trials for chronic kidney disease.

The company's lead clinical program, DMX 200, has been granted Orphan Drug Designation status in the U.S. for a medical condition called Focal Segmental Glomerulosclerosis (FSGS).

The innovative treatment combines two existing drugs.


ACCESS THE FULL PRESENTATION HERE



Register here to be notified of future DXB Company articles
View full DXB profile

Dimerix Timeline

Newswire
January 23 2017
Newswire
September 10 2014

Related Articles

Vaxil at the vanguard of immuno-oncology
January 07 2017
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.
blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
Drugs
February 07 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use